Related Experiment Video
Updated: Dec 27, 2025
11:05
Author Spotlight: A Battery of Highly Reproducible Behavioral Tests to Validate an Angelman Syndrome Murine Model
Published on: October 20, 2023
5.6K
Angelman Syndrome: From Mouse Models to Therapy
Diana C Rotaru1, Edwin J Mientjes1, Ype Elgersma1
1Department of Neuroscience, The ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Neuroscience
|February 24, 2020
Summary
Angelman syndrome (AS) is a neurodevelopmental disorder caused by the absence of UBE3A protein. AS mouse models are vital for understanding AS pathology and developing gene reactivation therapies.
Area of Science:
- Genetics and Molecular Biology
- Neuroscience
- Developmental Biology
Background:
- Angelman syndrome (AS) is a severe neurodevelopmental disorder (NDD) linked to chromosome 15q11-q13 deletions/duplications.
- AS results from the lack of functional maternal UBE3A protein, with the paternal copy silenced in neurons.
- Patients exhibit profound developmental delay, motor deficits, speech absence, intellectual disability, epilepsy, and sleep disturbances.
Purpose of the Study:
- To investigate the pathophysiology of Angelman syndrome using established mouse models.
- To identify potential therapeutic targets and treatment windows for AS.
- To evaluate the role of the UBE3A gene and its isoforms in AS pathology.
Main Methods:
- Utilized Angelman syndrome (AS) mouse models that recapitulate human disease features.
- Examined brain-wide effects of UBE3A loss, including neuronal excitability and synaptic changes.
- Investigated inducible AS mouse models to determine critical treatment timeframes.
- Assessed the contribution of the nuclear UBE3A isoform to AS pathology.
Main Results:
- Loss of UBE3A impacts multiple brain regions, increasing neuronal excitability and causing synaptic spine loss.
- Inducible AS mouse models revealed critical windows for therapeutic intervention.
- The nuclear UBE3A isoform plays a significant role in AS pathogenesis.
- AS mouse models have guided the development of Ube3a gene reactivation therapies.
Conclusions:
- AS mouse models are essential tools for understanding disease mechanisms and therapeutic development.
- Ube3a gene reactivation therapies show significant promise for treating Angelman syndrome.
- Further research into UBE3A's function and the nuclear isoform is crucial for advancing AS treatments.
